CNC

TentativeAI Memo

Centene

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

medium

Horizon

—

Key catalyst

2026 EPS guidance reaffirmed, not raised • 2026-09-16

Base target: $61 / p=50% prob

Biggest risk

Approximately $0.50 of the guidance increase came from non-recurring items, at-risk membership declined year over year, and the Q2 Medicaid health benefits ratio was 93.9%. These limit confidence in extrapolating Q2 earnings. [#SEC-8K-2026-07-28]

Invalidation

Break below $47 or thesis failure.

What would change my mind?

The reaffirmed EPS floor and improved Q2 Commercial and Medicare health benefits ratios support a profitability-recovery case if gains prove recurring. Wellcare's announced 2027 offerings create a concrete enrollment test, but no favorable outcome is established. [#8-K-2026-09-16] [#SEC-8K-2026-07-28] [#PR-2026-10-01]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-02

Base target

$61

p=50%

Bull target

$74

p=25%

Bear target

$47

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Earnings quality amid membership contraction
The reaffirmed EPS floor and improved Q2 Commercial and Medicare health benefits ratios support a profitability-recovery case if gains prove recurring.
Wellcare's announced 2027 offerings create a concrete enrollment test, but no favorable outcome is established.

BearKey bullets

At-risk membership fell to 25.9 million from 28.0 million year over year.
[#SEC-8K-2026-07-28]
Non-recurring Medicare and Commercial items contributed approximately $0.50 to the 2026 guidance increase.

WatchKey bullets

2026 EPS guidance reaffirmed, not raised

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $61 (p=50%)

Target spread vs base: +21% / -23%

Scenario probabilities

Bull Target: $74 (p=25%)Base Target: $61 (p=50%)Bear Target: $47 (p=25%)

Commentary

The October 27 earnings event and October 15 Medicare enrollment start are company-confirmed dates, but their outcomes, CNC-specific price reaction and analyst revisions are unavailable. The zero-valued sentiment fields indicate missing observations, not neutral readings. Supplied recent headlines offer little CNC-specific reaction evidence. The deterministic prior remains neutral with small expected returns, favoring monitoring over a bullish upgrade. [#IR-2026-10-27] [#PR-2026-10-01]

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Earnings quality amid membership contraction

Scenarios

Bull Target (Scenario probability)

$74 / p=25% prob

Base Target (Scenario probability)

$61 / p=50% prob

Bear Target (Scenario probability)

$47 / p=25% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-16
2026 EPS guidance reaffirmed, not raised
Centene reaffirmed full-year GAAP diluted EPS above $3.11 and adjusted diluted EPS above $4.80 on September 16; this was not a new increase. [#8-K-2026-09-16]
Prob 100.00% • Move 1.00% • Priced-in 95.00%
EVENT2026-10-15
Wellcare 2027 Medicare enrollment window
Wellcare announced its 2027 Medicare Advantage and Part D offerings ahead of the October 15–December 7 annual enrollment period. Dual-eligible members represent about 40% of its Medicare Advantage membership, and D-SNP products account for nearly half of its 2027 MA plan offerings. Enrollment and profitability effects remain unproven. [#PR-2026-10-01]
Prob 100.00% • Move 1.00% • Priced-in 70.00%
EVENT2026-10-27
October 27 Q3 earnings: test margin durability
Centene schedules its Q3 earnings event for October 27. Commercial, Medicare and Medicaid health benefits ratios, membership and any change to the reaffirmed EPS outlook will test whether Q2's improvement is recurring; no result is presumed. [#IR-2026-10-27] [#SEC-8K-2026-07-28] [#8-K-2026-09-16]
Prob 100.00% • Move 5.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Earnings quality amid membership contraction
2026-12-31
Approximately $0.50 of the 2026 guidance increase reflected non-recurring Medicare and Commercial items, while Q2 at-risk membership was 25.9 million versus 28.0 million a year earlier. Sustained recurring profitability remains an unconfirmed year-end test; December 31 is an analytical checkpoint, not an announced event. [#SEC-8K-2026-07-28]
Prob 60% • Move -7% • Priced-in 60%

Risks

At-risk membership fell to 25.9 million from 28.0 million year over year. [#SEC-8K-2026-07-28]
Non-recurring Medicare and Commercial items contributed approximately $0.50 to the 2026 guidance increase. [#SEC-8K-2026-07-28]
Q2 Medicaid health benefits ratio of 93.9% leaves medical-cost execution important to the recovery thesis. [#SEC-8K-2026-07-28]
The September disclosure reaffirmed rather than increased guidance; a further upward revision is not established. [#8-K-2026-09-16]
Wellcare's 2027 plan announcement does not establish enrollment gains or improved margins; plan enrollment also depends on contract renewal. [#PR-2026-10-01]

Peers

Symbol	Summary
ELV	Elevance offers a broader managed-care cross-check: its Q2 2026 release reported an 89.7% consolidated benefit expense ratio and elevated medical-cost trend in government businesses. Its diversified Carelon operations and different mix limit direct valuation comparison with Centene. Elevance Q2 release
MOH	Molina is a direct Medicaid, Medicare and Marketplace managed-care comparator. Its Q2 2026 release reported Medicaid and Medicare medical care ratios of 92.7% and 90.7%, versus Centene's 93.9% and 89.5% health benefits ratios; segment mix and accounting definitions limit a mechanical comparison. Molina Q2 release [#SEC-8K-2026-07-28]

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

ELV

Elevance offers a broader managed-care cross-check: its Q2 2026 release reported an 89.7% consolidated benefit expense ratio and elevated medical-cost trend in government businesses. Its diversified Carelon operations and different mix limit direct valuation comparison with Centene. Elevance Q2 release

MOH

Molina is a direct Medicaid, Medicare and Marketplace managed-care comparator. Its Q2 2026 release reported Medicaid and Medicare medical care ratios of 92.7% and 90.7%, versus Centene's 93.9% and 89.5% health benefits ratios; segment mix and accounting definitions limit a mechanical comparison. Molina Q2 release [#SEC-8K-2026-07-28]